RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
RetinalGenix Technologies (OTCQB:RTGN) has partnered with LabCorp to launch its DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. The collaboration enables patients to undergo genetic testing and high-resolution retinal imaging anonymously at any USA-based LabCorp location.
The platform analyzes blood, tears, nasal secretions, and saliva using proprietary algorithms to correlate genetic and retinal biomarkers for early disease detection. The service aims to reduce dependency on expensive diagnostic procedures like MRIs and CT scans, while making screening more accessible and cost-effective.
The company is working with regulators to establish CPT codes to lower healthcare costs and improve access to evaluations. High-resolution retinal imaging will be introduced as an additional service at various locations in the future.
RetinalGenix Technologies (OTCQB:RTGN) ha stretto una collaborazione con LabCorp per lanciare la sua piattaforma DNA/RNA/GPS Pharmaco-Genetic Mapping™. Questa partnership permette ai pazienti di effettuare test genetici e imaging retinico ad alta risoluzione in modo anonimo presso qualsiasi sede LabCorp negli Stati Uniti.
La piattaforma analizza sangue, lacrime, secrezioni nasali e saliva utilizzando algoritmi proprietari per correlare biomarcatori genetici e retinici, favorendo la diagnosi precoce delle malattie. Il servizio mira a ridurre la dipendenza da esami diagnostici costosi come risonanze magnetiche e TAC, rendendo gli screening più accessibili e convenienti.
L'azienda sta collaborando con le autorità regolatorie per stabilire codici CPT che abbassino i costi sanitari e migliorino l'accesso alle valutazioni. In futuro, l'imaging retinico ad alta risoluzione sarà offerto come servizio aggiuntivo in diverse sedi.
RetinalGenix Technologies (OTCQB:RTGN) se ha asociado con LabCorp para lanzar su plataforma DNA/RNA/GPS Pharmaco-Genetic Mapping™. Esta colaboración permite a los pacientes realizar pruebas genéticas y obtener imágenes retinianas de alta resolución de forma anónima en cualquier ubicación de LabCorp en Estados Unidos.
La plataforma analiza sangre, lágrimas, secreciones nasales y saliva usando algoritmos patentados para correlacionar biomarcadores genéticos y retinianos para la detección temprana de enfermedades. El servicio busca reducir la dependencia de procedimientos diagnósticos costosos como resonancias magnéticas y tomografías, haciendo los exámenes más accesibles y económicos.
La empresa está trabajando con reguladores para establecer códigos CPT que disminuyan los costos de atención médica y mejoren el acceso a evaluaciones. En el futuro, se ofrecerá la imagen retiniana de alta resolución como un servicio adicional en varias ubicaciones.
RetinalGenix Technologies (OTCQB:RTGN)는 LabCorp와 협력하여 DNA/RNA/GPS Pharmaco-Genetic Mapping™ 플랫폼을 출시했습니다. 이 협력으로 환자들은 미국 내 모든 LabCorp 지점에서 익명으로 유전자 검사와 고해상도 망막 촬영을 받을 수 있게 되었습니다.
이 플랫폼은 혈액, 눈물, 비강 분비물, 침을 독자적인 알고리즘으로 분석하여 유전자 및 망막 바이오마커를 연관 지어 조기 질병 진단을 가능하게 합니다. 이 서비스는 MRI나 CT 같은 고가의 진단 절차에 대한 의존도를 줄이고, 검진을 보다 접근하기 쉽고 비용 효율적으로 만드는 것을 목표로 합니다.
회사는 의료 비용 절감과 평가 접근성 향상을 위해 규제 기관과 협력하여 CPT 코드를 마련 중이며, 향후 다양한 지점에서 고해상도 망막 촬영 서비스를 추가로 제공할 예정입니다.
RetinalGenix Technologies (OTCQB:RTGN) s’est associé à LabCorp pour lancer sa plateforme DNA/RNA/GPS Pharmaco-Genetic Mapping™. Cette collaboration permet aux patients de réaliser des tests génétiques et des images rétiniennes haute résolution de manière anonyme dans n’importe quel centre LabCorp aux États-Unis.
La plateforme analyse le sang, les larmes, les sécrétions nasales et la salive à l’aide d’algorithmes propriétaires pour corréler des biomarqueurs génétiques et rétiniens en vue d’une détection précoce des maladies. Ce service vise à réduire la dépendance aux procédures diagnostiques coûteuses telles que l’IRM et la tomodensitométrie, tout en rendant le dépistage plus accessible et économique.
L’entreprise travaille avec les régulateurs pour établir des codes CPT afin de diminuer les coûts de santé et d’améliorer l’accès aux évaluations. L’imagerie rétinienne haute résolution sera proposée comme service additionnel dans plusieurs sites à l’avenir.
RetinalGenix Technologies (OTCQB:RTGN) hat eine Partnerschaft mit LabCorp geschlossen, um seine DNA/RNA/GPS Pharmaco-Genetic Mapping™ Plattform einzuführen. Diese Zusammenarbeit ermöglicht es Patienten, anonyme genetische Tests und hochauflösende Netzhautbildgebung an jedem LabCorp-Standort in den USA durchzuführen.
Die Plattform analysiert Blut, Tränen, Nasensekrete und Speichel mithilfe proprietärer Algorithmen, um genetische und netzhautbezogene Biomarker für die Früherkennung von Krankheiten zu korrelieren. Der Service zielt darauf ab, die Abhängigkeit von teuren Diagnoseverfahren wie MRTs und CT-Scans zu verringern und das Screening zugänglicher sowie kosteneffizienter zu gestalten.
Das Unternehmen arbeitet mit Regulierungsbehörden zusammen, um CPT-Codes zu etablieren, die die Gesundheitskosten senken und den Zugang zu Untersuchungen verbessern sollen. Hochauflösende Netzhautbildgebung wird zukünftig als zusätzlicher Service an verschiedenen Standorten angeboten.
- Partnership with major laboratory service provider LabCorp expands nationwide access
- Platform potentially reduces reliance on expensive diagnostic procedures
- Anonymous and confidential testing provides enhanced patient privacy
- Proprietary algorithms and technology could establish new screening standards
- Working towards CPT codes establishment for improved healthcare cost management
- Company is still in developmental stage
- High-resolution retinal imaging service not yet available
- CPT codes not yet established
- Revenue generation timeline unclear
Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms
APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation’s largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.
Through this collaboration, patients may visit any USA-based LabCorp location to have blood, tears, nasal secretions, and saliva collected and analyzed using proprietary algorithms developed by the RetinalGenix and DNA/RNA GPS analysis platform. These tests may correlate genetic and retinal biomarkers seeking to establish a new standard for early detection of a wide range of health conditions. Based on tests recommended by RetinalGenix, patients may elect to have their data analyzed using specific algorithms developed by RetinalGenix. This process is paired with DNA/RNA/GPS to correlate with current and future biomarkers found in the eye and the blood.
Dr. Larry Perich, DO, Advisor for the DNA/RNA/GPS program, noted, “As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care.”
Patients maintain full control of their health records, which remain anonymous and confidential. Appointments and test orders are managed via the RetinalGenix online platform, with results securely released to patients upon validation of payment at their chosen LabCorp center.
Dr. Taimour Langaee, PhD, oversees the Company's DNA/GPS genotyping/sequencing data processing, genetic and pharmacogenomics data analyses, and clinical genetic association studies between eye diseases and genetic variations. Dr. Langaee said, “I am excited that this creates great opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases, affecting millions of people and the potential to discover novel genetic variants and treatments.”
High-resolution retinal imaging will be introduced by RetinalGenix as a value-added additional service at various locations in the near future. The integration of high-resolution imaging is expected to further boost diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening.
These innovations are designed to make screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages.
“The cost of healthcare is enormous, and patient access is critical. This cost-effective methodology aims to reduce reliance on expensive diagnostic procedures such as MRIs, CT scans, PET Scans, echocardiograms to name a few, helping to alleviate the financial burden on both patients and the healthcare system. Equally important is avoiding the use of high-priced specialists to perform basic eye care services. The company is actively collaborating with regulators to establish CPT codes, which should lower healthcare costs and improve access to necessary evaluations. By doing so, the already overburdened patient assessment process can be streamlined,” stated Jerry Katzman, MD, RetinalGenix Technologies CEO.
About RetinalGenix
RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding reducing reliance on expensive diagnostic procedures with the Company’s methodology, the planned rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, the program providing insights into both ocular and systemic diseases, correlating genetic and retinal biomarkers to seek to establish a new standard for the early detection of a wide range of health conditions, the value of platforms for diagnosing both ocular and systemic diseases continuing to grow, promising improved outcomes and more accessible care, the opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases and the potential to discover novel genetic variants and treatments, introducing high-resolution retinal imaging as an additional service in the near future, the integration of high-resolution imaging further boosting diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening, the innovations making screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages, establishing CPT codes to further lower healthcare costs and improve access to necessary evaluations and streamlining the patient assessment process. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Media Contact:
For further information, please contact:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
FAQ
What is the partnership between RetinalGenix (OTCQB:RTGN) and LabCorp?
How does RetinalGenix's DNA/GPS platform work?
What are the potential cost benefits of RetinalGenix's platform?
When will RetinalGenix introduce high-resolution retinal imaging services?
How does RetinalGenix protect patient privacy?
